ADCYAP1 and Parkinson disease: Most importantly, it was demonstrated that our PACAP glycopeptide analogues, specifically 2LS80Mel and 2LS98Lac, were able to elicit neuroprotection in animal models of TBI and a mild-lesion model of PD.